Results 201 to 210 of about 864,738 (314)

Probing Electrocatalyst Design for Product Selectivity in CO2 Reduction

open access: yesAdvanced Science, EarlyView.
Selective CO2 electroreduction is controlled by catalyst structure, dynamic surface reconstruction, adsorbate interactions, and reaction microenvironment. This review summarizes Cu‐ and non‐Cu‐based catalysts, single‐atom and molecular systems, degradation pathways, and operando/computational strategies for steering CO2RR toward hydrocarbons ...
Suvodeep Sen   +5 more
wiley   +1 more source

Ultrasound‐Activated Piezoelectric Neuroimmune Hydrogel Orchestrates Neurogenesis‐Macrophage Crosstalk in Diabetic Wound Healing

open access: yesAdvanced Science, EarlyView.
In this work, we design an ultrasound‐activated piezoelectric hydrogel platform (AOEF@AP5+US) that reprograms neurogenesis‐macrophage crosstalk as an integrated strategy to overcome the intertwined barriers of chronic inflammation, peripheral neuropathy, and impaired regeneration in diabetic wounds.
Kai Wang   +13 more
wiley   +1 more source

Programming Structural Symmetry and Emission in Low‐Dimensional Hybrid Perovskites via Time and Temperature

open access: yesAdvanced Science, EarlyView.
We demonstrate programmable structural symmetry and emission in benzylammonium‐based low‐dimensional hybrid perovskites. Continuous shaking transforms orthorhombic platelets into a lower‐symmetry monoclinic phase with broadband emission, whereas thermal activation drives the reverse pathways toward a higher‐symmetry configuration resembling the ...
Luiz G. Bonato   +7 more
wiley   +1 more source

Modeling of Hidden Structures Using Sparse Chemical Shift Data from NMR Relaxation Dispersion. [PDF]

open access: yesBiophys J, 2021
Fenwick RB   +4 more
europepmc   +1 more source

An Aggregation‐Induced Polymerization Poly(Disulfide)‐Drug Nanoplatform for Autoimmune Uveitis Therapy via Inhibiting the cGAS‐STING Pathway

open access: yesAdvanced Science, EarlyView.
A cationic poly(disulfide)‐drug nanoplatform (LA/DexP) was developed to treat experimental autoimmune uveitis (EAU). With potent blood‐retinal barrier penetrability, LA/DexP releases DSP in response to high ROS and scavenges cfDNA to inhibit the cGAS‐STING signaling pathway.
Yuelan Wu   +12 more
wiley   +1 more source

Home - About - Disclaimer - Privacy